SPINK9

SPINK9 is a Kazal-type serine protease inhibitor expressed predominantly in palmo-plantar epidermis that selectively inhibits kallikrein-related peptidase 5 (KLK5) with an apparent Ki of 65 nM, functioning through a reactive loop (residues 48–49) whose His48 becomes protonated at the acidic pH of outer skin layers, strengthening KLK5 binding by decreasing the dissociation rate and fitting into KLK5's negatively charged active-site pocket (PMID:19194479, PMID:22505519). Beyond protease inhibition, constitutively secreted SPINK9 transactivates EGFR via purinergic receptor-dependent ADAM metalloprotease activation to promote keratinocyte migration, representing a protease-inhibitor-independent signaling function (PMID:24441102). SPINK9 also acts as a selective antimicrobial peptide that kills E. coli by entering bacterial cells and targeting the periplasmic chaperone SKP, with killing activity dependent on the same reactive loop sequence required for KLK5 inhibition (PMID:30468739).

1. 2009 High

   Identification of SPINK9 as a selective, high-affinity KLK5 inhibitor in human skin established the first known endogenous protease-specific regulator in stratum corneum, answering how excessive KLK5 activity is controlled at the skin surface.

   Evidence Two independent groups purified native SPINK9 from stratum corneum and demonstrated selective KLK5 inhibition (Ki ~65 nM) with no activity against KLK7, KLK14, trypsin, plasmin, or thrombin using recombinant protein assays and SPR

   PMID:19190773 PMID:19194479

   Open questions at the time

   • Structural basis of KLK5 selectivity over other kallikreins not yet determined
   • In vivo relevance of SPINK9-KLK5 interaction in desquamation not demonstrated
   • No loss-of-function genetic evidence linking SPINK9 deficiency to skin disease
2. 2012 High

   Mutagenesis of the reactive loop defined the molecular determinants of KLK5 selectivity and revealed a pH-sensitive inhibition mechanism, explaining how SPINK9 function strengthens in the acidic outer epidermis where KLK5 control is most needed.

   Evidence Site-directed mutagenesis of reactive loop residues 48–49 combined with enzyme kinetics showed His48 protonation at low pH decreases dissociation rate from KLK5; molecular modeling showed complementary fit into KLK5's negatively charged pocket

   PMID:22505519

   Open questions at the time

   • No experimental crystal structure of the SPINK9-KLK5 complex
   • pH-dependent inhibition not validated in intact skin tissue
   • Contribution of reactive loop to selectivity against non-kallikrein proteases not systematically tested
3. 2014 Medium

   Discovery that SPINK9 transactivates EGFR via purinergic receptor-ADAM signaling to drive keratinocyte migration revealed an unexpected signaling role independent of protease inhibition, broadening its function from protease regulation to wound repair.

   Evidence Recombinant SPINK9 treatment of keratinocytes induced EGFR phosphorylation and migration; blocked by purinergic receptor antagonists (oxidized ATP, PPADS), metalloproteinase inhibitor, and EGFR-blocking antibody

   PMID:24441102

   Open questions at the time

   • Direct receptor target of SPINK9 on the keratinocyte surface not identified
   • In vivo wound healing relevance not tested
   • Signaling pathway not confirmed in a second laboratory or cell system
4. 2018 Medium

   Demonstration that SPINK9 enters and kills E. coli by targeting the chaperone SKP established a dual antimicrobial function for this protease inhibitor, linking innate skin defense to the same reactive loop required for KLK5 inhibition.

   Evidence Native SPINK9 variants isolated from stratum corneum killed E. coli strains; electron microscopy showed bacterial entry; co-immunoprecipitation identified SKP as binding partner; Skp-deletion mutants showed increased sensitivity

   PMID:30468739

   Open questions at the time

   • Mechanism by which SPINK9 enters bacterial cells is unknown
   • How reactive loop mediates both protease inhibition and antimicrobial killing simultaneously is unresolved
   • Antimicrobial activity tested only against E. coli; spectrum against skin-relevant commensals and pathogens is narrow

• The in vivo physiological importance of SPINK9 — whether its loss causes desquamation defects, impaired wound healing, or increased susceptibility to skin infection — remains untested in genetic models or human disease cohorts.
• No knockout or knockdown animal model exists
• No human genetic variants linked to skin disease
• Relative contributions of KLK5 inhibition, EGFR transactivation, and antimicrobial activity to skin homeostasis are undefined